Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Arcus Biosciences ( (RCUS) ) just unveiled an update.
Arcus Biosciences, Inc. recently completed a public offering of its common stock, selling a total of 15,755,000 shares at $18.25 per share, including the full exercise of the underwriters’ option. The offering, which closed on November 3, 2025, generated approximately $269.7 million in net proceeds for the company, after accounting for underwriting discounts, commissions, and estimated expenses.
The most recent analyst rating on (RCUS) stock is a Buy with a $56.00 price target. To see the full list of analyst forecasts on Arcus Biosciences stock, see the RCUS Stock Forecast page.
Spark’s Take on RCUS Stock
According to Spark, TipRanks’ AI Analyst, RCUS is a Neutral.
Arcus Biosciences’ stock score is primarily influenced by strong technical momentum, despite significant financial and valuation challenges. The stock’s bullish trend is a key positive, but the company’s financial struggles and negative valuation metrics weigh heavily on the overall score.
To see Spark’s full report on RCUS stock, click here.
More about Arcus Biosciences
Average Trading Volume: 1,081,317
Technical Sentiment Signal: Buy
Current Market Cap: $2.13B
For detailed information about RCUS stock, go to TipRanks’ Stock Analysis page.